Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 631,300 shares, a growth of 437.3% from the January 15th total of 117,500 shares. Based on an average trading volume of 3,650,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 3.6% of the shares of the stock are short sold.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 32.23% of the stock is owned by institutional investors and hedge funds.

Virpax Pharmaceuticals Stock Performance

NASDAQ:VRPX opened at $0.27 on Thursday. The company has a 50-day moving average of $0.33 and a 200-day moving average of $0.60. Virpax Pharmaceuticals has a twelve month low of $0.23 and a twelve month high of $5.48.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.